ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $406,516 | -25.8% | 15,129 | -1.5% | 0.01% | -14.3% |
| Q2 2023 | $547,559 | +30.2% | 15,355 | -7.3% | 0.01% | +16.7% |
| Q1 2023 | $420,573 | -36.4% | 16,558 | +1.6% | 0.01% | -45.5% |
| Q4 2022 | $660,925 | +22.6% | 16,295 | -0.1% | 0.01% | +10.0% |
| Q3 2022 | $539,000 | -6.1% | 16,308 | +0.1% | 0.01% | -16.7% |
| Q2 2022 | $574,000 | -18.9% | 16,293 | +5.8% | 0.01% | 0.0% |
| Q1 2022 | $708,000 | -30.3% | 15,396 | +0.4% | 0.01% | -25.0% |
| Q4 2021 | $1,016,000 | +4.3% | 15,329 | -1.8% | 0.02% | -11.1% |
| Q3 2021 | $974,000 | -27.6% | 15,603 | -4.0% | 0.02% | -28.0% |
| Q2 2021 | $1,345,000 | +78.6% | 16,246 | +43.0% | 0.02% | +56.2% |
| Q1 2021 | $753,000 | -27.8% | 11,363 | -16.4% | 0.02% | -30.4% |
| Q4 2020 | $1,043,000 | +78.9% | 13,587 | +0.4% | 0.02% | +64.3% |
| Q3 2020 | $583,000 | -2.2% | 13,529 | -1.9% | 0.01% | -6.7% |
| Q2 2020 | $596,000 | – | 13,797 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |